ArticleCureus2025
Imaging the Future: Diagnosing Treatable Neurometabolic Disorders in Children.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neurodevelopmental disorders in children: the role of MRI in early detection and intervention planning.Frontiers in neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inborn errors of metabolism are a prevalent cause of pediatric neurological abnormalities, often resulting from enzyme deficiencies that disrupt metabolic pathways. Understanding the radiological manifestations of these disorders is critical for timely diagnosis and therapy. This study aimed to elucidate the magnetic resonance imaging (MRI) brain characteristics and magnetic resonance spectroscopy (MRS) findings of specific treatable pediatric neurometabolic disorders through clinical vignettes, thereby enhancing diagnostic accuracy and informing therapeutic approaches. The study includes four cases with varying presentations, all confirmed by genetic testing, and utilized magnetic resonance imaging and spectroscopy to identify characteristic features. The first case, diagnosed as thiamine metabolism dysfunction syndrome type 4, exhibits bilateral corpus striatum T2 hyperintensities with diffusion restriction on MRI brain, increased lactate peak, and reduced N-acetylaspartate (NAA) on magnetic resonance spectroscopy (MRS), and SLC25A19 gene mutation on genetic analysis - features consistent with biotin-thiamine-responsive basal ganglia disease. The second case, identified as thiamine metabolism dysfunction syndrome type 2, reveals T2 hyperintensities in the bilateral corpus striatum, medial thalami, and cerebellar white matter, along with restricted diffusion, reduced NAA, and an inverted lactate doublet on MRS, with genetic analysis confirming an SLC19A3 mutation, also falling under the spectrum of biotin-thiamine-responsive basal ganglia disease. The third case, representing cerebral creatine deficiency syndrome type 2, demonstrates bilateral symmetric T2 hyperintensities in the globus pallidus and central tegmental tracts, a characteristic absence of a creatine peak on MRS, and a confirmed guanidomethyl transferase (GAMT) deficiency gene mutation. The fourth case, diagnosed as hypermanganesemia with dystonia type 2, is characterized by T1 hyperintensity and T2 hypointensity involving the bilateral globus pallidi, substantia nigra, and dentate nuclei, with genetic testing revealing an SLC39A14 mutation. The study emphasizes the importance of MR imaging and spectroscopy in identifying pediatric neurometabolic diseases that can be treated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.